Audio Journal of Oncology COPENHAGEN, Denmark—In a phase 1b study patients with previously untreated stage IV pancreatic cancer responded or derived “clinical benefit” from a regimen in wh
Audio Journal of Oncology
COPENHAGEN, Denmark—In a phase 1b study patients with previously untreated stage IV pancreatic cancer responded or derived “clinical benefit” from a regimen in which a Wnt-signaling inhibitor—the humanized monoclonal antibody vantictumab—was added to nab-paclitaxel and gemcitabine chemotherapy. Colin Weekes MD PhD, Associate Professor at the University of Colorado in Denver, who reported findings from the trial at the 2016 European Society for Medical Oncology (ESMO) congress, discusses their clinical implications with Peter Goodwin. Debashis Sarker MD FRCP, Senior Lecturer and Consultant in Medical Oncology, at Guy’s, St Thomas’ and King’s College Hospitals, London, who was not involved with the study.
Related Episodes
Charles E Geyer MD; ESMO 2025: Antibody Drug Conjugate T-DXd Brings Longer Cancer-Free Survival for Patients with HER2-Positive Early Breast Cancer and Residual Invasive Disease
Charles E Geyer MD, at ESMO 2025, discusses DESTINY-Breast05 results, revealing trastuzumab deruxtecan (T-DXd) significantly improves disease-free survival for HER2-positive early breast cancer patients with residual invasive disease after neoadjuvant therapy. T-DXd outperformed trastuzumab emtansin
Li Zhang MD; ESMO 2025: Patients with EGFR-mutated Lung Cancer Progressing After Tyrosine Kinase Therapy Live Longer with Sacituzumab Tirumotecan Therapy
Antibody Drug Conjugate Prolongs Life in NSCLC refractory to EGFR TKI Therapy
Xiuning Le MD PhD; ESMO 2025: Sevabertinib Success for Patients with HER2-Mutated Non-Small Cell Lung Cancer in SOHO-01 Study
A new anti cancer drug sevabertinib, that targets mutated HER2, has proved effective in the SOHO-01 study among patients wiith HER2 mutated non small cell lung cancer. It has now been reported in the